Untargeted metabolomics and mendelian randomization analysis identify adrenic acid as a novel biomarker of Type 2 diabetes mellitus.

Given the differences between Chinese T2DM patients and those of other ethnicities, understanding the metabolic contributions in this population is essential. This study aimed to identify T2DM-associated metabolic biomarkers through clinical untargeted metabolomics and mendelian randomization (MR).

This study included 120 Chinese participants, including 60 patients with T2DM and 60 control subjects. We employed ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) for non-targeted metabolomics analysis of plasma metabolites. Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to identify T2DM-related metabolites. Integration of metabolomics and MR data identified novel key biomarkers for T2DM.

LC-MS/MS-based untargeted metabolomics identified 71 up-regulated and 37 down-regulated metabolites in the Chinese T2DM patients. In MR analysis, 52 metabolites exhibited causal associations with the risk of T2DM. Integrating metabolomic analysis with genetic evidence-based causal inference collectively confirmed that higher adrenic acid (AdA) were associated with increased risk of T2DM and positively correlated with fasting blood glucose (FBG). The main metabolic impacted pathways were unsaturated fatty acids biosynthesis, linoleic acid metabolism.

Increased plasma AdA level was associated with higher FBG and an elevated risk of T2DM, suggesting that AdA represents a probable biomarker for T2DM.
Diabetes
Diabetes type 2
Care/Management

Authors

Wang Wang, Li Li, Yan Yan, Xu Xu, Wu Wu, Zhu Zhu, Chen Chen, Meng Meng, Li Li, Yao Yao
View on Pubmed
Share
Facebook
X (Twitter)
Bluesky
Linkedin
Copy to clipboard